Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

Despite the development of new antineoplastic agents for the treatment of colorectal cancer (CRC), oxaliplatin and fluoropyrimidines remain the most commonly employed drugs for the treatment of both early and advanced disease. Intrinsic or acquired resistance is, however, an important limitation to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Perez, Marco, Lucena-Cacace, Antonio, Marín-Gómez, Luis Miguel, Padillo-Ruiz, Javier, Robles-Frias, Maria Jose, Saez, Carmen, Garcia-Carbonero, Rocio, Carnero, Amancio
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078079/
https://ncbi.nlm.nih.gov/pubmed/27105527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8880
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky